AU2023230976A1 - Continuous dosing regimen for treatment of a condition of the eye - Google Patents

Continuous dosing regimen for treatment of a condition of the eye Download PDF

Info

Publication number
AU2023230976A1
AU2023230976A1 AU2023230976A AU2023230976A AU2023230976A1 AU 2023230976 A1 AU2023230976 A1 AU 2023230976A1 AU 2023230976 A AU2023230976 A AU 2023230976A AU 2023230976 A AU2023230976 A AU 2023230976A AU 2023230976 A1 AU2023230976 A1 AU 2023230976A1
Authority
AU
Australia
Prior art keywords
drug delivery
day
vorolanib
insert
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023230976A
Other languages
English (en)
Inventor
Jay S. DUKER
Owen N. DURHAM
Michelle Howard-Sparks
Basel KARZOUN
Nancy LURKER
Dario PAGGIARINO
Said Saim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals Inc
Original Assignee
Eyepoint Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Inc filed Critical Eyepoint Pharmaceuticals Inc
Publication of AU2023230976A1 publication Critical patent/AU2023230976A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023230976A 2022-03-11 2023-03-10 Continuous dosing regimen for treatment of a condition of the eye Pending AU2023230976A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263318823P 2022-03-11 2022-03-11
US63/318,823 2022-03-11
US202263320984P 2022-03-17 2022-03-17
US63/320,984 2022-03-17
US202263341456P 2022-05-13 2022-05-13
US63/341,456 2022-05-13
US202263390051P 2022-07-18 2022-07-18
US63/390,051 2022-07-18
PCT/US2023/064148 WO2023173093A1 (en) 2022-03-11 2023-03-10 Continuous dosing regimen for treatment of a condition of the eye

Publications (1)

Publication Number Publication Date
AU2023230976A1 true AU2023230976A1 (en) 2024-09-19

Family

ID=85937358

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023230976A Pending AU2023230976A1 (en) 2022-03-11 2023-03-10 Continuous dosing regimen for treatment of a condition of the eye

Country Status (9)

Country Link
US (1) US20250186398A1 (https=)
EP (1) EP4489750A1 (https=)
JP (1) JP2025507154A (https=)
KR (1) KR20240156416A (https=)
AU (1) AU2023230976A1 (https=)
CA (1) CA3245209A1 (https=)
IL (1) IL315333A (https=)
TW (1) TW202400143A (https=)
WO (1) WO2023173093A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
AU2021340733A1 (en) * 2020-09-14 2023-05-18 EyePoint Pharmaceuticals, Inc. Bioerodible ocular drug delivery insert and therapeutic method
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2565683T3 (es) 2006-09-15 2016-04-06 Xcovery, Inc. Compuestos inhibidores de quinasa
WO2018059556A1 (zh) 2016-09-29 2018-04-05 贝达药业股份有限公司 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
EP4537830A3 (en) * 2017-06-13 2025-06-11 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
AU2021340733A1 (en) * 2020-09-14 2023-05-18 EyePoint Pharmaceuticals, Inc. Bioerodible ocular drug delivery insert and therapeutic method

Also Published As

Publication number Publication date
IL315333A (en) 2024-10-01
WO2023173093A1 (en) 2023-09-14
KR20240156416A (ko) 2024-10-29
JP2025507154A (ja) 2025-03-13
TW202400143A (zh) 2024-01-01
US20250186398A1 (en) 2025-06-12
CA3245209A1 (en) 2023-09-14
WO2023173093A9 (en) 2023-12-07
EP4489750A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
EP4210682B1 (en) Bioerodible ocular drug delivery insert and therapeutic method
US20250186398A1 (en) Continuous dosing regimen for treatment of a condition of the eye
TW200538135A (en) Extended therapeutic effect ocular implant treatments
JP2009535422A (ja) 血管作動薬を含有する持続放出性眼内インプラント
US20250205152A1 (en) Method of preventing age-related macular degeneration by administering an ocular drug delivery insert
US20250186336A1 (en) Method of treating wet age-related macular degeneration
US20260083727A1 (en) Pharmaceutical formulations of nintedanib for intraocular use
CN118871107A (zh) 用于治疗眼睛病症的持续给药方案
CN118891040A (zh) 治疗湿性年龄相关性黄斑变性的方法
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
HK40118703A (zh) 治疗湿性年龄相关性黄斑变性的方法
HK40118701A (zh) 用於治疗眼睛病症的持续给药方案
CN118871106A (zh) 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法
HK40118700A (zh) 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法
HK40073855A (en) Bioerodible ocular drug delivery insert and therapeutic method